Creatinine, eGFR and albuminuria: how should kidney function be assessed?
One blood marker, one filtration estimate, and one urine marker of damage. Kidney assessment is incomplete when only one is considered.
The quick answer
Creatinine, eGFR, and albuminuria answer complementary—not interchangeable—questions.
Serum creatinine is a filtration marker influenced by muscle production and other non-kidney factors. eGFR uses creatinine—and sometimes cystatin C—to estimate filtration. Urine albumin-to-creatinine ratio (uACR) looks for albumin leakage, a marker of kidney damage and cardiovascular risk. Current guidance recommends assessing at-risk people with both GFR and urine albumin, then confirming chronicity and unexpected abnormalities.
Creatinine — the raw marker
A waste product related to muscle metabolism that is filtered and partly secreted by the kidneys. A value cannot be interpreted reliably without age, sex, muscle context, prior results, and the estimating equation.
eGFR — the filtration estimate
An equation-based estimate reported in mL/min/1.73 m². It is more informative than creatinine alone but is still an estimate, especially when creatinine is unstable or muscle mass is unusual.
uACR — the damage signal
Compares urine albumin with urine creatinine, usually in a spot sample. Albuminuria may reveal kidney damage even when eGFR is preserved and adds independent prognostic information.
The central distinctionCreatinine supplies a marker. eGFR translates it into an estimate of filtration. uACR asks whether albumin is leaking through the kidney. Function and damage must be read together.
Side by side
Four measurements. Four different roles.
KDIGO 2024 classification
CKD risk is mapped on two axes: GFR and albuminuria.
The G and A categories are interpreted together with cause and persistence. G1 or G2 alone does not define CKD without another marker of kidney damage.
GFR categories
Albuminuria categories
MERHI ONE Evidence Map
What the evidence supports—and what one result cannot prove.
Each rating applies to the exact statement. Some recommendations are based on strong prognostic evidence and international consensus rather than randomized trials of the laboratory test itself.
Assess people at risk for CKD with both GFR and urine albumin measurement.1,2,3,7,8
KDIGO 2024 recommends testing at-risk people using both measures because low filtration and albuminuria identify overlapping but different groups. Diabetes, hypertension, cardiovascular disease, prior acute kidney injury, family history, and structural disease are important examples of risk contexts.
CKD requires a kidney abnormality with health implications that persists for at least three months.1,2,7
Examples include eGFR <60 mL/min/1.73 m², persistent uACR ≥30 mg/g, urine sediment abnormalities, structural abnormalities, or other markers. A single low eGFR or high uACR does not by itself establish chronicity.
eGFR is more informative than serum creatinine interpreted alone.1,3,4,5
The same creatinine concentration can correspond to different filtration estimates depending on age and sex. A creatinine value inside a laboratory reference interval can coexist with clinically important loss of filtration, especially in an older or low-muscle-mass adult.
Creatinine-based eGFR can be inaccurate when creatinine generation or kidney function is unstable.1,4
Extremes of muscle mass or body size, amputation, frailty, paralysis, bodybuilding, severe illness, cancer, unusual diet, and acute kidney injury can weaken the relationship between creatinine and true GFR. Some medications alter tubular secretion of creatinine without equivalent loss of filtration.
Albuminuria adds kidney and cardiovascular risk information independently of eGFR.1,2,6,8
Risk rises across the A categories and becomes greater when lower GFR and higher albuminuria occur together. A preserved eGFR does not neutralize persistent albuminuria, and low eGFR can occur without albuminuria.
An abnormal uACR should usually be confirmed because albumin excretion varies.1,3,6,8
Exercise, fever, urinary infection, menstruation, acute illness, marked hyperglycemia, and uncontrolled blood pressure can transiently raise albumin excretion. A first-morning midstream sample is preferred when feasible; a quantitative uACR is favored over dipstick alone.
Combining creatinine and cystatin C can improve eGFR accuracy.1,4,5,6
KDIGO and KDOQI support creatinine–cystatin C eGFR when more accurate assessment can affect diagnosis, prognosis, drug dosing, or another clinical decision. The two markers have different non-GFR determinants and can complement each other.
A normal serum creatinine rules out kidney disease.1,3,4
Creatinine may remain within the laboratory range despite reduced eGFR, and albuminuria or structural disease can be present with preserved filtration. Early kidney disease is often asymptomatic.
Every asymptomatic adult without risk factors should receive routine CKD screening at a fixed interval.1,2,9
KDIGO supports testing people at risk. In the U.S., the USPSTF is updating its CKD screening review and explicitly states that its 2012 recommendation is out of date; a new population-wide recommendation is not yet final at this review date.
Two native pathways
The core classification is international. Implementation differs by health system.
United States — KDIGO / KDOQI
- Use a race-free validated eGFR equation; the 2021 CKD-EPI creatinine equation is widely recommended in U.S. practice.
- When accuracy can change a decision, creatinine–cystatin C eGFR is preferred over either marker alone.
- Quantitative spot uACR is the preferred adult test for albuminuria; first-morning midstream collection improves standardization when practical.
- USPSTF screening guidance is currently being updated; its website says the 2012 statement is out of date, so specialty and risk-based guidance should be consulted.
Brazil — PCDT / SBD
- The national PCDT defines CKD by structural or functional abnormality persisting for at least three months and uses GFR and markers of kidney damage in evaluation.
- Brazilian diabetes guidance recommends both CKD-EPI 2021 eGFR and spot urine ACR for diabetic kidney disease screening; in type 2 diabetes, screening begins at diagnosis.
- An abnormal ACR in diabetes should be confirmed in two of three samples within six months because of daily variability.
- Laboratory method, equation, access to cystatin C, referral pathways, and medication coverage must be localized to the Brazilian health system.
Reading combinations
The pattern tells more than any isolated number.
eGFR ≥60 + uACR <30 mg/g
Usually reassuring when stable and no other kidney-damage marker exists. It does not exclude structural disease, urine sediment abnormalities, or an acute clinical problem.
eGFR ≥60 + persistent uACR ≥30 mg/g
Can meet CKD criteria despite preserved filtration. The albuminuria category, cause, blood pressure, diabetes status, and overall cardiovascular risk matter.
eGFR <60 + uACR <30 mg/g
May represent nonalbuminuric CKD if persistent. Review age, trajectory, muscle mass, medications, imaging, urine sediment, and whether cystatin C would change interpretation.
eGFR <60 + uACR ≥30 mg/g
Both filtration and damage markers are abnormal; combined risk is higher as eGFR falls and uACR rises. Confirmation, cause evaluation, treatment review, and referral criteria deserve attention.
Creatinine rises rapidly
Steady-state eGFR may be misleading. Evaluate acute kidney injury, volume status, obstruction, illness, medications, and laboratory context promptly.
eGFR and cystatin C disagree
The difference may reflect non-GFR determinants of either marker. The combined equation is often more accurate, but the clinical context still decides which estimate is most credible.
Common interpretation errors
Kidney numbers are easy to oversimplify.
The main danger is treating an estimate, a single sample, or a reference interval as a complete diagnosis.
‘My creatinine is normal, so my kidneys are normal’
Creatinine must be translated into eGFR and paired with urine albumin and clinical context.
‘eGFR 60 means my kidneys work at exactly 60%’
eGFR is an indexed estimate in mL/min/1.73 m², not a direct percentage of kidney function.
‘One abnormal test proves chronic disease’
CKD requires persistence for at least three months, unless prior evidence already establishes chronicity. Acute abnormalities need prompt evaluation.
‘Normal eGFR excludes kidney damage’
Albuminuria, hematuria, structural disease, or other damage markers can exist while filtration remains preserved.
‘Foamy urine proves protein loss’
Foam is nonspecific. Albuminuria requires laboratory measurement, ideally quantitative uACR.
‘A 24-hour urine is always better’
For routine adult albuminuria screening and monitoring, a spot uACR is generally preferred. Timed collections are reserved for selected questions.
What a wrong interpretation can cause
- Missed CKD despite a ‘normal’ creatinine
- False CKD labeling from one transient result
- Unnecessary anxiety or repeat testing
- Unsafe medication dosing from an unreliable estimate
- Failure to investigate acute kidney injury
- Delayed cardiovascular and kidney risk reduction
A practical next step
Turn three numbers into a reliable kidney assessment.
- 01
Define why testing is being done: risk-based screening, acute change, CKD confirmation, monitoring, or medication dosing are different questions.
- 02
Review serum creatinine together with the reported eGFR, equation, prior values, muscle context, diet/supplements, medications, and clinical stability.
- 03
Measure quantitative spot uACR in people at risk; use a first-morning sample when feasible and check urinalysis or other tests when the question requires them.
- 04
Repeat unexpected eGFR or uACR abnormalities to establish persistence and exclude transient factors, without delaying evaluation of a possible acute problem.
- 05
Classify confirmed CKD by cause, GFR category, and albuminuria category; use the combination for prognosis and follow-up intensity.
- 06
Consider creatinine–cystatin C eGFR or measured GFR when the creatinine estimate is unreliable and greater accuracy could change a consequential decision.
Frequently asked
Direct answers to the questions people actually ask.
Is creatinine 1.2 mg/dL normal?+
The number cannot be judged reliably without age, sex, muscle mass, assay range, prior values, and eGFR. The same creatinine can represent different filtration in different people.
Does a normal eGFR rule out kidney disease?+
No. Persistent albuminuria, urine sediment abnormalities, imaging findings, or other markers can diagnose kidney disease despite eGFR ≥60.
What uACR is considered abnormal?+
KDIGO categories are A1 <30, A2 30–300, and A3 >300 mg/g. A value ≥30 mg/g can support CKD only when persistent or when chronicity is otherwise established.
Are microalbumin and urine albumin-to-creatinine ratio the same thing?+
Not exactly. ‘Microalbumin’ is an older, potentially misleading term for moderately increased urine albumin; uACR is the preferred quantitative measurement that corrects urine albumin for urine creatinine.
Do I need a 24-hour urine collection?+
Usually not for routine adult albuminuria screening. A quantitative spot uACR is practical and guideline-preferred; timed collection is reserved for selected situations.
Can exercise change uACR?+
Yes. Strenuous exercise and several temporary conditions can increase albumin excretion. An unexpected result should usually be repeated under stable conditions.
When is cystatin C useful?+
When muscle mass or another factor makes creatinine unreliable, or when a more accurate eGFR could change diagnosis, drug dosing, procedure eligibility, or another important decision.
When should a kidney result be evaluated urgently?+
A rapid creatinine rise, major fall in urine output, severe swelling or breathlessness, confusion, persistent vomiting, suspected obstruction, marked electrolyte abnormality, or systemic illness warrants prompt assessment.
Claim-level foundation
References
Priority was given to KDIGO 2024, the 2025 U.S. KDOQI commentary, official NIDDK laboratory resources, Brazil’s national PCDT, and current Brazilian diabetes guidance. Citations beside each claim point to its supporting sources.
- 01Open source ↗
Kidney Disease: Improving Global Outcomes · 2024
Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- 02Open source ↗
KDIGO · 2024
Executive Summary of the CKD Evaluation and Management Guideline
- 03Open source ↗
National Institute of Diabetes and Digestive and Kidney Diseases · Current resource
Chronic Kidney Disease Tests & Diagnosis
- 04Open source ↗
National Institute of Diabetes and Digestive and Kidney Diseases · Reviewed 2025
Clinical Measurements and eGFR Accuracy
- 05Open source ↗
National Institute of Diabetes and Digestive and Kidney Diseases · Current resource
eGFR Equations for Adults
- 06Open source ↗
KDOQI / National Kidney Foundation · 2025
U.S. Commentary on the KDIGO 2024 CKD Guideline
- 07Open source ↗
Ministério da Saúde / Conitec · 2024; updated 2025
Brazilian Clinical Protocol: Strategies to Slow CKD Progression
- 08Open source ↗
Sociedade Brasileira de Diabetes · 2026 edition
Evaluation and Treatment of Diabetic Kidney Disease
- 09Open source ↗
U.S. Preventive Services Task Force · Update in progress
Chronic Kidney Disease: Screening
Editorial record